FXR activation represses lipogenic pathways and is a promising target for MASLD therapy [157] FXR-activating drug candidates include obeticholic acid (OCA), EDP-305, INT-767, and non-steroidal compounds like MET409, tropifexor, cilofexor, vonafexor, and TERN-101 [140]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.